Open label extension studies: Research or marketing?

British Medical Journal

Volumn 331, Issue 7516, 2005, Pages 572-574

  Taylor, G J ^a,c   Wainwright, P ^b  

^a University of Bath   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c Department of Nursing ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL RESEARCH; PATIENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; BIOMEDICAL AND BEHAVIORAL RESEARCH; DRUG SCREENING; ETHICS; FORECASTING; HUMAN EXPERIMENT; MARKETING; METHODOLOGY; PATIENT SELECTION;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

DRUG EVALUATION; ETHICS, MEDICAL; FORECASTING; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; MARKETING; PATIENT SELECTION;

EID: 24644446896     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.331.7516.572     Document Type: Review

References (4)

1. Micetich KC. The ethical problems of the open label extension study. Camb Q Health Ethics 1996;5:410-4.
2. Wainwright P. Consent to open label extension studies: some ethical issues. J Med Ethics 2002;28:373-6.
3. Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Geneva: World Health Organization, 2002.
4. Blader JC. Can keeping clinical trial participants blind to their study treatment adversely affect subsequent care? Contemp Clin Trials 2005;26: 290-9.